Acción CRNO B CERENO SCIENTIFIC AB
Añadir a una lista
Para utilizar esta función debe ser un cliente o miembro.
ConéctateRegístrate

Otros idiomas Cereno Scientific AB

Acciones

CRNO B

SE0008241558

Mercado cerrado - Nasdaq Stockholm
Otros sitios de cotización
 18:00:00 28/06/2024 		Varia. Cinco días. Varia. 1 de enero.
4,756 SEK +9,33 % Gráfico intradía de Cereno Scientific AB +8,68 % +3,96 %
28/06 Dosificación del primer sujeto en el primer ensayo en humanos de fase I del novedoso inhibidor de HDAC Cs014 de Cereno Scientific CI
28/06 Cereno Scientific AB (Publ) anuncia que el ensayo de fase Ii con Cs1 en la hipertensión arterial pulmonar está cerrando el reclutamiento y procediendo a la línea de máxima actividad CI

Otros idiomas

Buscar
Ver los resultados
Desbloquee todas las noticias: ¡Sea el primero en enterarse y reaccione antes que los mercados!
Inscripción 100% Gratuita
First subject dosed in Cereno Scientifics first-in-human Phase I trial of novel HDAC inhibitor CS014
First Subject Dosed in Cereno Scientifics First-In-Human Phase I Trial of Novel Hdac Inhibitor Cs014
Cereno Scientific's Phase II trial with CS1 in Pulmonary Arterial Hypertension is closing for recruitment and proceeding to topline
Cereno Scientific AB Announces Phase Ii Trial with Cs1 in Pulmonary Arterial Hypertension Is Closing for Recruitment and Proceeding Topline
Cereno Scientific releases BioStock interview with CEO Sten R. Sörensen regarding CS014 advancing to clinical Phase I
BioStock: Cereno's CEO - "CS014 adds potential for cardiovascular disease patients"
Cereno Scientific Gets EU Approval for First-In-Human Trial for Antithrombotic Drug Candidate
Cereno Scientific granted approval from, EMA to initiate first-in-human Phase I trial with novel epigenetic HDAC inhibitor, CS014
Cereno Scientific Receives Approval from, EMA to Initiate First-In-Human Phase I Trial with Novel Epigenetic HDAC Inhibitor, CS014
Preclinical data for Cereno Scientific's drug candidate CS585 showing high selectivity for the IP receptor presented at the EHA 2024 Hybrid Congress
Cereno Scientific AB Presents Preclinical Data At EHA 2024 Hybrid Congress
Cereno Scientific moves to new office space at GoCo Health Innovation City in Gothenburg
Cereno Scientific Moves to New Office Space At GoCo Health Innovation City in Gothenburg
Cereno Scientific initiates collaboration with the Pulmonary and Vascular Research Institute (PVRI)
Cereno Scientific AB Initiates Collaboration with the Pulmonary and Vascular Research Institute
Cereno Scientific to present preclinical data for drug candidate CS585, a novel IP receptor agonist, at the ESC Congress 2024
Cereno Scientific participating at BIO 2024, June 3-6, San Diego
Cereno Scientific publishes the interim report for Q1 2024 ( January 1-March 31)
Cereno Scientific AB Reports Earnings Results for the First Quarter Ended March 31, 2024
Cereno Scientific presents at ABGSC Investor Days, May 23
No hay resultados para esta búsqueda
Todas Recomendaciones analistas Eventos destacados Insiders Transcripts Comunicados Publs. oficiales Otros idiomas Ideas de trading Artículos de MarketScreener Estrategias MarketScreener

Filtros

Buscar

Fecha de publicación

De

Hasta

  1. Bolsa de valores
  2. Acciones
  3. Acción CRNO B
  4. Noticias Cereno Scientific AB
  5. Otros idiomas